Published online Jul 15, 2020. doi: 10.4251/wjgo.v12.i7.719
Peer-review started: March 25, 2020
First decision: April 26, 2020
Revised: May 3, 2020
Accepted: May 27, 2020
Article in press: May 27, 2020
Published online: July 15, 2020
Almost 90% cases of pancreatic cancer can be detected with the mutation activation of KRAS gene. Ras mutated tumors have been shown to express a highly active nuclear factor-κB (NF-κB) signaling pathway. NF-κB in pancreatic cancer with KRAS gene mutation was in a persistent activation state, which was closely related to the high expression of P62.
To detect the expression level of P62 in pancreatic cancer and find the relationship among P62, P65, and clinicopathological features, which will provide a theoretical basis for the prevention of pancreatic cancer and postponement of its development.
This study aimed to investigate the clinical characteristics of patients with pancreatic carcinomas and evaluate the relationship among P62, P65, and clinicopathological features.
Typical tumor tissue chips were used to detect the expression of phospho-P65 and P62 by immunohistochemical staining. SPSS 22.0 software was used to analyze the relationship between the expression of phosphor-P65 and P62 and the clinico-pathological features of pancreatic carcinoma samples.
P62 was mainly expressed in the cytoplasm of pancreatic carcinoma cells, and phospho-P65 was mainly expressed in the nucleus and cytoplasm of pancreatic carcinoma cells. Aprroximately 94.3% of phospho-P65 positive tissues showed positive P62 expression in pancreatic carcinomas. And 89.2% of P62 positive tissues showed positive phospho-P65 expression in pancreatic carcinomas. There was a significant difference in P62 expression among different T stages of pancreatic carcinoma.
P62 could be used as a valuable malignant indicator for human pancreatic carcinomas.
The correlation between clinicopathological features and P62 expression could be used to predict the prognosis in patients with pancreatic cancer. NF-kB and P62 may be new targets for future carcinoma therapy.